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Abstract
The primary analysis of randomized cancer screening trials for cancer typ-
ically adheres to the intention-to-screen (ITT) principle, measuring cancer-
specific mortality reductions between screening and control arms. These mor-
tality reductions result from a combination of the screening regimen, screening
technology and the effect of the early, screening-induced, treatment. This moti-
vates addressing these different aspects separately. Here we are interested in the
causal effect of early versus delayed treatments on cancer mortality among the
screening-detectable subgroup, which under certain assumptions is estimable
from conventional randomized screening trial using instrumental variable type
methods. To define the causal effect of interest, we formulate a simplified causal
multi-state model for screening trials, based on a hypothetical intervention trial
where screening detected individuals would be randomized into early versus de-
layed treatments. The cancer-specific mortality reductions after screening de-
tection are quantified by a cause-specific hazard ratio. For this, we propose two
estimators, based on an estimating equation and a likelihood expression. The
methods extend existing instrumental variable methods for time-to-event and
competing risks outcomes to time-dependent intermediate variables. Using the
causal model as a data generating mechanism, we investigate the performance
of the new estimators, and compare them to two previously proposed ones. In
addition, we illustrate the proposed method in the context of CT screening for
lung cancer using the US National Lung Screening Trial (NLST) data.
Keywords: Causal inference, Instrumental variable estimation, Multi-state
model, Randomized screening trial
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1 Introduction
The benefits of cancer screening are ideally studied through randomized screening
trials, where asymptomatic participants are assigned to either undergo a prespecified
regimen of screening examinations, or to control without screening, and then followed
up for cancer specific mortality (Hu and Zelen, 1997). The primary analysis of such
a trial usually follows the intention to screen (ITT) principle, based on comparison
of cancer specific mortality between the screening and control arms at the end of the
follow-up period. Any mortality reductions in the screening arm are due to the combi-
nation of earlier (asymptomatic) detections due to the screening technology, and the
effectiveness of the subsequent early (versus delayed, following symptomatic diagno-
sis) treatments. This motivates studying these two aspects separately. Herein we are
interested in the effectiveness of the early treatments in the subpopulation who would
be screening detectable if offered screening. The subgroup effectiveness can be stud-
ied based on data collected through conventional screening trials, using instrumental
variable type estimators, where the instrument is the randomized assignment.
Instrumental variable (IV) approach has been primarily introduced to adjust for
non-compliance with the treatment assignments in therapeutic trials (Angrist et al.,
1996; Baiocchi et al., 2014). Several authors have utilized the IV approach in screen-
ing trials for estimating the effect of screening assignment among the compliers, a
latent subgroup of participants who adhere to the assigned screening regimen (Baker,
1998; Roemeling et al., 2007). This is different from the present context where our in-
terest is in the effectiveness of early treatments in the screening detectable subgroup;
IV estimators are applicable also for this purpose, and can estimate the mortality risk
reduction in the screening detectable subgroup. For this purpose, McIntosh (1999)
formulated instrumental variable type estimators in a cohort diagnosed with cancer,
assembled after sufficiently long follow-up period to have similar numbers of cancer
cases in both screening and control arms to avoid overdiagnosis bias. In Saha et al.
(2018) we defined the effect measures and estimators as functions of time, and for-
mulated the estimators in the entire trial cohort, which avoids any selection bias due
to conditioning on intermediate variables in instrumental variable analysis (Swanson
et al., 2015).
If the screening is discontinued sufficiently early in the trial and the subsequent
follow-up is sufficiently long, the estimators proposed in Saha et al. (2018) also esti-
mate the case-fatality reduction due to the early treatments, though they are valid
for subgroup mortality risk reduction even without this interpretation, which is im-
portant if the screening regimen continues for the duration of the trial. We connected
the effect measures to a hypothetical intervention trial proposed by Miettinen (2014,
2015), where screening-detected individuals would be randomized into early versus
delayed treatments. Although such a trial could not be implemented in practice, it
is helpful in formulating meaningful causal estimands that can then be estimated
from conventional screening trials. In a different context, treatment effect in a latent
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subgroup has been studied by Altstein et al. (2011); Altstein and Li (2013), in a di-
agnostic setting where immediate lymph node removal surgery is received by patients
with a positive biopsy test while those with a negative biopsy test receive a control
regimen of observation, with the causal effect of the immediate surgery among the
positive biopsy subgroup as the quantity of interest. The screening trial context dif-
fers from this due to the repeated rounds of screening, making the latent subgroup
membership time-dependent.
Recent methodological literature has seen several proposals for instrumental vari-
able estimation with time-to-event and competing risks outcomes. The latter is rel-
evant for the screening context as the interest is in cancer-specific mortality. In-
strumental variable estimators generalize to time-to-event outcomes most straightfor-
wardly by considering time-specific risk or survival probability as the outcome and
using plug-in estimators that can accomodate censoring such as the Kaplan-Meier
estimator (Nie et al., 2011). This approach generalizes to competing risks outcomes
by using non-parametric cumulative incidence estimators (Richardson et al., 2017).
Instrumental variable approaches to estimate causal effect parameters in causal pro-
portional hazards (Martinussen et al., 2019) and additive hazards (Zheng et al., 2017;
Martinussen and Vansteelandt, 2020) models have also been proposed. The current
setting differs from these because the latent subgroup is time-dependent, accumulated
through repeated screening examinations. In Saha et al. (2018) we demonstrated that
the plug-in type estimation approach to instrumental variable estimation is still appli-
cable in this setting, connecting the causal quantities to the hypothetical intervention
trial. We also formulated the estimators under competing risks, and allowing for in-
clusion of covariates to account for covariate dependent censoring. Herein we aim to
extend the approach from estimating subgroup mortality risk reduction to estimat-
ing a causal hazard ratio. We broadly follow the approach of (Martinussen et al.,
2019) for instrumental variable estimation for causal Cox proportional hazards mod-
els, but extend this approach for the time-dependent latent subgroup. The challenges
in formulating causal estimands with time-dependent exposure in a multi-state model
setting have been discussed by von Cube et al. (2019). We make sure the quantities
are well-defined by linking them with the hypothetical intervention trial.
To test the methods, our second objective is to propose a causal model for random-
ized screening trial that can be used as a data generating mechanism in simulation
studies. We aim for a simplified mechanism that avoids modeling the properties of
the screening technology (sensivity, specifity), sojourn time (the period where asymp-
tomatic cancer is screening-detectable), lead time (the period between screening de-
tection and clinical detection in the absence of screening) and stage transition of the
cancer. This is in line with our focus on the causal subgroup treatment effects among
the screening detectable. In contrast, the well-known Hu-Zelen model and its exten-
sions which have been used for planning screening trials (Zelen, 1993; Hu and Zelen,
1997; Lee and Zelen, 2006), parameter estimation (Shen and Zelen, 1999; Sung et al.,
2019) and could also serve as a simulation model. These models are based on mod-
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eling the natural history of the disease and the properties of the screening test. We
aim to avoid specifying these parts of the model by basing the causal model on the
hypothetical intervention trial, where the causal effects of early treatments following
an early detection are quantified through a hazard ratio. We will apply the simula-
tion mechanism to compare the performance of the different measures suggested for
subgroup mortality reduction, and further use simulation to answer the question of
whether conventional screening trials are powered to detect such subgroup effects.
The remainder of the paper is structured as follows: in Section 2 we introduce the
necessary notation, define the causal model, and describe the algorithm to simulate
data mimicking screening trials. In Section 3, we discuss the identifying assumptions
for estimation under this model, and introduce a new estimator to quantify the ef-
fect of early treatments in the screening-detectable subgroup as a hazard ratio. We
presented a simulation study to compare all the estimators in Section 4, in terms of
bias, power and coverage probability. In Section 5, we illustrate the use of the new
estimator using data from the US National Lung Screening Trial (NLST). Finally, a
brief discussion and future directions are presented in Section 6.
2 A causal model for randomized screening trials
2.1 Conventional screening trial
We introduce the necessary notation in the context of the US National Lung Screening
Trial, where heavy smokers, currently smoking or having quit within the last 15 years,
with a smoking history of 30+ pack years, aged between 55 − 74, were assigned at
random to undergo three annual screening examination or control. The participants
were asymptomatic of lung cancer at the time of randomization. Participants in the
screening arm received three annual low-dose helical CT scans, whereas participants in
the control arm received a standard chest X-ray, and both arms were followed up for 7
years for the main analysis (NLST Research Team, 2011). In the following, we assume
the X-ray screening to have negligible mortality benefits, as has been demonstrated
by Oken et al. (2011), and equate it to no screening. We characterize the causal
effect of screening-induced early treatments through a simplified causal multi-state
model where the mortality benefits manifest after an early detection through a CT
scan. From the healthy state (numbered as state 1), participants in the screening
arm have three possible transitions: early diagnosed through CT screening (state 2),
cancer-specific death without early diagnosis (state 3) and other-cause death (state
4). In addition, from the early diagnosed state, the participants can move to cancer-
specific death or other-cause death states, with potentially different transition rates.
Since the control arm does not have early diagnosis by definition, only transitions
from state 1 to states 3 and 4 are possible. For concise notation, we use counting
processes. We note that since each particular type of transition in a multi-state model
can be characterized through a competing risks model, the transition intensities are
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analogous to the causal cause-specific hazards, as outlined by Young et al. (2020),
but conditional on the event histories taken place so far.
Let N zkl(t) ∈ {0, 1} be the potential (underlying, in the absence of censoring)
counting process that counts the transitions of a given individual from state k to
l by time t in arm z, where k 6= l; k, l ∈ {1, 2, 3, 4} and z = 1, or 0 indicate
the screening or control arms, respectively. In the current context each transition
can take place at most once, and thus each counting process only counts to one,
with states 3 and 4 being absorbing states. The corresponding observed process is
formulated as Nkl(t) = ZN
1
kl(t) + (1− Z)N0kl(t), where Z is the arm that the patient
actually was assigned to in the randomized screening trial. The counting processes
are characterized by the transition intensities defined as
λzkl(t) = lim
∆t→0
P (N zkl(t+ ∆t)−N zkl(t−) = 1 | Hz(t−))
∆t
where Hz(t−) indicates the history of states until time t−. We note that the model
could be alternatively specified in discrete time through the conditional probabilities
P (N zkl(t + ∆t) − N zkl(t−) = 1 | Hz(t−)) ≈ λzkl(t)∆t, but we will use continuous time
notation for simplicity. The corresponding cumulative transition intensity function
is defined as Λzkl(t) =
∫ t
s
λzkl(t) dt. The transition intensities can be collected into a
matrix
λz(t) =
1 2 3 4
1 −∑4l=2 λz1l(t) λz12(t) λz13(t) λz14(t)
2 0 −∑4l=3 λz2l(t) λz23(t) λz24(t)
3 0 0 0 0
4 0 0 0 0
In the conventional screening trials, the ITT estimand would be defined by com-
paring the outcomes between the two arms at time t after sufficiently long follow-up,
in terms of the cumulative incidences for cancer-specific mortality. For example, the
absolute reduction in cancer-specific mortality risk would be measured by
E[N013(t)]− E[N113(t) +N123(t)] (1)
and the proportional reduction by
1− E[N
1
13(t) +N
1
23(t)]
E[N013(t)]
(2)
The estimation of these quantities does not requite a multi-state model, as the com-
ponents could be estimated through empirical cumulative incidences in the two arms.
However, the multi-state model is needed to specify and estimate the causal effect of
the early treatment among the early detectable subgroup. This subgroup is latent
at baseline and accumulates in the screening arm during the follow-up of the trial
through the repeated screening examinations. Since screening itself is not an inter-
vention, the mortality benefits can manifest only after an early detection. To specify
the correponding causal effect, we need to introduce a well-defined intervention.
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2.2 Hypothetical intervention trial
Following and extending (Miettinen, 2015), we can envision a trial that has simi-
lar screening regimen as the screening arm of the conventional trial, but instead of
randomizing into screening and non-screening, screens everyone, and at the time of
an early detection, randomizes into referral to early treatment vs delayed treatment
through withholding the screening result. Delayed treatment refers treatments fol-
lowing a later symptomatic diagnosis. Since the early detection can take place only
once for a given individual, the randomization for the assignment in the event of early
detection can already take place at study baseline, which is relevant for the indexing
of the corresponding potential outcomes. A schematic illustration of the hypothetical
trial is presented in Figure 1, and the corresponding multi-state model in Figure 2.
While this kind of trial could not be implemented in practice, it is important as a
thought experiment to define the causal quantities that we are interested in.
Among N112(t) = 1 we define N
1r
2l (t) ∈ {0, 1}, l ∈ {2, 3} to be potential (underly-
ing) counting processes for subsequent death corresponding to early (r = 1) versus
delayed (r = 0) treatment, characterized by transition intensities
λ1r2l (t) = lim
∆t→0
P (N1r2l (t+ ∆t)−N1r2l (t−) = 1 | H1(t−))
∆t
.
The modified transition matrix is now
λ1r =
1 2 3 4
1 −∑4l=2 λ11l(t) λ112(t) λ113(t) λ114(t)
2 0 −∑4l=3 λ1r2l (t) λ1r23(t) λ1r24(t)
3 0 0 0 0
4 0 0 0 0
Under this model, the absolute cancer mortality mortality risk reduction in the
subgroup could be measured by
E[N1023 (t)−N1123 (t) | N112(t) = 1] (3)
and the proportional reduction by
1− E[N
11
23 (t) = 1 | N112(t) = 1]
E[N1023 (t) = 1 | N112(t) = 1]
. (4)
In a trial where the screening is discontinued at some point (as it was in NLST after
three annual rounds), and the follow-up is long enough so that all the mortality ben-
efits have been realized, these quantities approximate the absolute and proportional
case-fatality reduction. We discussed the estimation of these quantities in (Saha et al.,
2018).
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We note that the above does not yet assume anything about the early treatment
effect, for example generally this effect could be a function of time and/or function of
the time of the early diagnosis. However, we can simplify the model by characterizing
the effect as a constant ratio λ1023(t) = θλ
11
23(t), characterizing the early treatment effect
on cancer-specific mortality through a single parameter. In addition, although this
is not generally required, we take λ1024(t) = λ
11
24(t), meaning that the early treatments
do not have effect on other-cause mortality. We take the time scale for all of the
transition intensities to be the time since the baseline/study entry. However, it would
also be equally possible to use the time since early detection as the time scale for the
transitions after the early detection, and to define proportionality of the effect on this
time scale.
Since the transition intensities λ102l (t) are not directly estimable from data observed
under a conventional randomized screening trial, the estimation requires instrumental
variable type methods, using the randomized assignment in the conventional trial as
an instrument. We will propose estimation methods in Section 3, but will first discuss
the use of the causal model for simulation.
Eligible for
screening and
randomized
Z = 1
(screening arm)
Z = 0
(control arm)
N113(t) + N
1
23(t) N
0
13(t)
(a) Conventional screening trial
Contrast: 1− E[N113(t)+N123(t)]
E[N013(t)]
or E[N013(t)]− E[N113(t) + N123(t)]
Eligible for
screening
Z = 1
(everyone
screened)
N112(t) = 1
(screening-detected
and randomized)
R = 1 (referral to
early treatment)
R = 0 (no referral
to early treatment)
N1123 (t) N
10
23 (t)
(b) Hypothetical intervention trial
Contrast: 1− E[N1123 (t)|N112(t)=1]
E[N1023 (t)|N112(t)=1]
or E[N1023 (t)−N1123 (t) | N112(t) = 1]
Figure 1: Illustration of a conventional randomized screening trial and a hypothetical
intervention trial sharing the same screening regimen, and the corresponding causal
contrasts.
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Healthy
(1)
Early detected
(2)
Cancer-specific death
(3)
Other-cause death
(4)
λ112(t)
λ113(t)
λ114(t)
λ1123(t)
λ1124(t)
λ1023(t) = θλ
11
23(t)
Figure 2: A schematic illustrating the transition intensities in the hypothetical inter-
vention trial. Here λkl(t) corresponds to the transition intensity from state k to state
l at time t. The dashed arrow represents cancer mortality under delayed treatments,
contrasted to early treatments, with the intensity ratio θ quantifying the causal effect
of interest.
2.3 Description of the simulation algorithm
To simulate data from the proposed causal multi-state model, one needs to fix the
transition intensities in the matrix λ1r, to simulate event histories in the two arms in
the hypothetical intervention trial, corresponding to r = 1 and r = 0. These event
histories are also used to represent event histories in the conventional screening trial.
In particular, the intervention arm (r = 1) event histories can be directly taken to
be event histories in the screening arm of the conventional trial, assuming that early
diagnosis in practice leads to early treatment, as would be the case at least in the lung
cancer context. Also, the control arm r = 0 event histories can be directly taken to be
event histories in the control arm by taking N012(t) = 0 and N
0
1l(t) = N
1
1l(t) +N
10
2l (t),
l ∈ {3, 4}, under the assumption that the screening test and being withheld the result
of it does not in itself modify the subsequent outcomes without the intervention.
For a simulation study, for example exponential or Weibull functional forms can
be assumed for the intensities, or the observable ones (λ11l(t), l ∈ {2, 3, 4} and λ112l (t),
l ∈ {3, 4}) can be estimated from the screening arm of an existing trial such as
the NLST, with the control arm (r = 0) counterparts obtained by fixing the effect
parameter θ to a value. With the transition intensity matrix λ1r, simulation can then
proceed through usual algorithms for simulating event histories from a multi-state
model as described for example in Beyersmann et al. (2011, p. 45). Briefly, this
proceeds by simulating the time and type of the next event from a competing risks
model, moving to a new state, and continuing the same. Starting from the healthy
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state, this would mean simulating the time of the first event, T , from the total hazard
Λ1(t) = Λ112(t) + Λ
1
13(t) + Λ
1
14(t),
which specifies the event time distribution F (t) = P (T ≤ t) = 1 − exp(−Λ1(t)).
Using the inverse cumulative distribution function method, we can take u ∼ U [0, 1]
and solve Λ1(t) + log(1− u) = 0 with respect to t to get the time. At time T = t the
type of the event is then drawn with multinomial probabilities
λ11l(t)
λ112(t) + λ
1
13(t) + λ
1
14(t)
for l ∈ {2, 3, 4}. If the new state is terminal (l ∈ {3, 4}), the algorithm stops,
otherwise it continues similarly from state 2, where the new total hazard is given by
Λ1r(t) = Λ1r23(t) + Λ
1r
24(t), and the event type probabilities by
λ1r2l (t)
λ1r23(t) + λ
1r
24(t)
for l ∈ {3, 4}. We used the NLST as the basis of the simulation study presented
in Section 4. For the observable transition intensities, we calculated smooth hazard
estimates using the (Hess and Gentleman, 2019) package in R and integrated them
numerically to get the corresponding cumulative intensities.
3 Hazard ratio estimation
To estimate the parameter θ from data collected under a conventional randomized
screening trial, in addition to the modeling assumption discussed in the previous
section, we need some identifying assumptions. In particular, we assume that (i)
N112(t) = 1 ⇒ N01l(t) = N102l (t), l ∈ {3, 4}, meaning that for someone who would
get early detected by time t, but not receive early treatment, the potential mortality
outcome would be the same as in the control arm of the conventional trial. Further,
we assume that N112(t) = 0 ⇒ N01l(t) = N11l(t), l ∈ {3, 4}, meaning that for some
who would not get early detected, the potential mortality outcome would be the
same between the two arms of the conventional trial. Essentially, assumptions (i)
and (ii) together state that screening examinations themselves (and being withheld
of the result) do not have impact on mortality in the absence of the intervention.
In addition, we assume that (iii) λ112l (t) = λ
1
2l(t), meaning that the mortality rates
under early treatment following early diagnosis can be estimated from the screening
arm of the conventional trial. Essentially, this means assuming that in practice early
treatment follows early diagnosis.
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3.1 Estimating equation
To derive a connection between the observable and unobservable quantities, we can re-
express the cancer-specific cumulative incidence in the control arm of a conventional
trial EN [013(t)] as the sum of two different alternative event histories in terms of the
latent subgroup membership of the individual, that is, the event history under early
detection and no early treatment and the event history under no early detection by
time t. This gives
E[N013(t)] = E[N
0
13(t) | N112(t) = 1]P (N112(t) = 1)
+ E[N013(t) | N112(t) = 0]P (N112(t) = 0)
= E[N1023 (t) | N112(t) = 1]P (N112(t) = 1)
+ E[N113(t) | N112(t) = 0]P (N112(t) = 0)
=
∫ t
0
exp
{−(Λ112(u) + Λ113(u) + Λ114(u))}λ112(u)
×
∫ t
u
exp
{−(θΛ123(v) + Λ124(v))} θλ123(v) dv du
+
∫ t
0
exp
{−(Λ112(u) + Λ113(u) + Λ114(u))}λ113(u) du. (5)
Here the second equality used assumptions (i) and (ii) and the third equality as-
sumption (iii), as well as the modeling assumption of proportional hazards. A related
equation was considered by McIntosh (1999), but without considering the hazard ra-
tio as the parameter of interest. The estimating equation proposed by Martinussen
et al. (2019) is also similar, but did not consider time-dependent latent subgroup.
We note that all the quantities on the right hand side of can be estimated from the
screening arm of the conventional trial, while the left hand size can be estimated from
the control arm of the conventional trial. For semi-parametric estimation of θ, we use
non-parametric plug-in estimates for the other quantities in (5).
State occupation probabilities in a multi-state model can be generally estimated
using the non-parametric Aalen-Johansen approach (Borgan, 2014), which in the case
of a competing risks setting reduces to the non-parametric cumulative incidence esti-
mator for the left hand side of the equation. The required plug-in inputs for the right
hand side are Nelson-Aalen/Breslow estimates for the cumulative hazards/hazard in-
crements; using these as inputs (with one of them modified by the multiplicative
factor θ), the Aalen-Johansen state occupation probabilities can be calculated for ex-
ample using the msfit and probtrans functions of the mstate package (Putter et al.,
2007; de Wreede et al., 2011). Equation (5) can then be solved numerically with re-
spect to log θ to estimate the early treatment effect. The approach can accommodate
independent censoring through the plug-in estimates. The fixed time t at which the
estimating equation is evaluated can be chosen as the maximum follow-up length, or,
as we demonstrate in Section 5, the effect can be estimated as a function of t to see
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if the estimates stabilize over the follow-up period.
We note that we can obtain an analogous equation
E[N014(t)] =
∫ t
0
exp
{−(Λ112(u) + Λ113(u) + Λ114(u))}λ112(u)
×
∫ t
u
exp
{−(θΛ123(v) + Λ124(v))}λ124(v) dv du
+
∫ t
0
exp
{−(Λ112(u) + Λ113(u) + Λ114(u))}λ114(u) du. (6)
for other-cause mortality. However, this is not needed for estimation as we have only
one unknown quantity to solve under the assumption that early treatments do not
have effect on other-cause mortality.
3.2 Maximum likelihood estimation
Alternatively to the estimating equation approach, we can consider a multinomial
likelihood expression for the parameter θ using data from the mortality outcomes in
the conventional trial. This can be written as
L(θ) =
∏
{i:Zi=1}
{
E[N113(t) +N
1
23(t)]
N113(t)E[N114(t) +N
1
24(t)]
N114(t)
× (1− E[N113(t) +N123(t)]− E[N114(t) +N124(t)])(1−N113(t)−N114(t)) }
×
∏
{i:Zi=0}
E[N013(t)]
N013(t)E[N014(t)]
N014(t)
× (1− E[N013(t)]− E[N014(t)])(1−N013(t)−N014(t))
θ∝
∏
{i:Zi=0}
E[N013(t)]
N013(t)E[N014(t)]
N014(t)
× (1− E[N013(t)]− E[N014(t)])(1−N013(t)−N014(t)) , (7)
where E[N013(t)] and E[N
0
14(t)] are as in (5) and (6). The proportionality followed
because, considering the transition intensities in the screening arm as fixed quantities,
the likelihood contributions of the individuals in the screening arm do not depend
on θ. In practice, for semi-parametric estimation, the transition intensities in (5)
and (6) can be replaced with non-parametric plug-in estimates, and the expression
L(θ) then maximized numerically with respect to log θ. Instead of evaluating the
likelihood expression at a fixed time t, independent censoring can be accommodated
by evaluating the likelihood contributions at the minimum of the time of death or
censoring time.
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4 Simulation study
To compare the estimators proposed in Section 3, we generated data using the algo-
rithm described in Section 2.3, using the NLST as the basis of the simulation study.
In addition, we compared the statistical power of tests based on these to the two esti-
mators we had proposed earlier for absolute and proportional subgroup mortality risk
reduction. In the present notational framework, these estimators can be expressed as
(3) =
E[N13(t) | Z = 0]− E[N13(t) +N23(t) | Z = 1]
E[N12(t) | Z = 1] , (8)
and
(4) =
E[N13(t) | Z = 0]− E[N13(t) +N23(t) | Z = 1]
E[N13(t) | Z = 0]− E[N13(t) | Z = 1] , (9)
where again expectations can be replaced with appropriate non-parametric cumulative
incidence estimators. While these are estimating mortality risk reductions rather than
the hazard ratio, the four estimators are comparable in terms of the power of a Wald-
type or confidence interval based test on them. This will help answer the question of
whether conventional screening trial such as NLST is powered to detect the subgroup
early treatment effect. For this reason, we also calculated estimates for the ITT
mortality reductions as
(1) = E[N13(t) | Z = 0]− E[N13(t) +N23(t) | Z = 1] (10)
and the proportional reduction by
(2) = 1− E[N13(t) +N23(t) | Z = 1]
E[N13(t) | Z = 0] , (11)
as the trial is powered for these.
To compare the four estimators, we generated 1000 NLST-like datasets, by fixing
the transition intensities to those estimated from the NLST, and fixing the hazard
ratio to 0.4804. For each dataset we simulated n = 53, 452 individuals assigned
randomly with equal probability to screening or control. Since in the NLST the cen-
soring is mostly administrative at the end of the follow-up at 7 years, we did not
simulate random censoring. The true values of the subgroup mortality reductions
were evaluated by calculating the quantities (3) and (4) under the specified transi-
tion intensities. In the estimators, the cumulative incidences were calculated using
the cuminc function of the cmprsk R package (Gray, 2019). For more complex state
occupation probabilities needed for evaluating the estimating equation and the like-
lihood expression, we first calculated Nelson-Aalen/Breslow estimators, which were
used as inputs to Aalen-Johansen estimators for state occupation probabilities using
the functions available in the mstate R package. The estimating equation was solved
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numerically using the uniroot function and the likelihood maximized numerically
using the optim function of R (R Core Team, 2017).
The mortality reductions, as well as the estimating equation (5) and the likeli-
hood expression (7) were evaluated at 7 years. To estimate standard errors for each
estimator, we boostrapped each simulated dataset 50 times, and took the standard
deviation of the point estimates as the standard error. This was compared to the
Monte Carlo standard deviation of the point estimates over the simulation rounds.
95% confidence intervals were constructed using the normal approximation and com-
pared to the nominal coverage probability. The power of the confidence interval based
test was calculated as the proportion of simulation rounds where the interval did not
cover the null value.
The simulation results are presented in Table 1. These indicate that all the esti-
mators could capture the corresponding true value relatively well, based on low bias
and near nominal coverage probability. The power of the subgroup treatment effect
estimators was also comparable to the ITT analysis. This can be explained by the
fact that all the mortality reduction due to screening is realized through the effect
of the early treatments, and thus focusing on the subgroup does not lose any of the
effect. The test based on the estimator (9) had the highest power. The two hazard
ratio estimators gave very similar results, so we only use the estimating equation for
the data analysis in the next section.
Estimator
Causal
Truth
Point
SE Power Coverage MCsd MCE
contrast estimate
(5) log θ 0.4804 0.4893 0.1628 0.85 0.942 0.1657 0.005
(7) log θ 0.4804 0.4892 0.1628 0.85 0.942 0.1657 0.005
(8) (3) 0.1512 0.1507 0.0521 0.83 0.945 0.0534 0.0017
(9) (4) 0.2986 0.2921 0.0804 0.90 0.944 0.0803 0.0025
(10) (1) 0.0036 0.0036 0.0012 0.85 0.940 0.0012 0.00004
(11) (2) 0.1616 0.1616 0.0500 0.87 0.938 0.0514 0.0016
Table 1: Comparison of subgroup and population-level estimators. The estimators
from top to bottom are estimating equation and likelihood based estimation of the
subgroup cancer mortality hazard ratio, absolute and proportional subgroup cancer
mortality reduction, and absolute and proportional population cancer mortality re-
duction. SE stands for standard error, MCsd for Monte Carlo standard deviation and
MCE for Monte Carlo error.
5 Illustration of the hazard ratio using NLST data
In the NLST, 53, 453 heavy smokers were randomized to either CT screening or
control arms, with three annual rounds of screening with the first round initiated
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at the baseline and subsequently followed for 7 years (NLST Research Team, 2011).
The original analysis followed the ITT principle. Here we are interested in quantifying
the effect of the early vs late treatments among the screening detectable subgroup
in terms of the subgroup cancer-specific mortality hazard ratio. For this purpose,
we carried out a secondary analysis of the NLST data using the estimating equation
approach based on (5). We estimated the hazard ratio as a function of the fixed
time point t, to determine if this effect stabilizes or dilutes over time. The confidence
intervals were generated using 500 bootstrap replicates.
The results are presented in Figure 3. This demonstrates that the hazard ratio
becomes statistically significant in the second year of follow-up, reaches a maximum
of 1.687 at around 6 years, and levels after that. Overall the effect estimate is rela-
tively stable over time which may lend some support towards the proportionality of
this effect. The maximum hazard ratio indicates a 100% × (1 − 1/1.687) = 40.7%
cancer-specific mortality hazard reduction due to the early treatments. This can be
contrasted to the empirical cancer mortality rate ratio between screening and control
arms in the trial which after 7 year of follow-up was 1−(469/171, 412)/(552/170, 355),
or around 15.6%. The reason for the difference between these two measures is that
the latter combines the effect of early treatments after early diagnosis with factors in-
fluencing early diagnosis itself, including the screening regimen, screening technology
and non-compliance. The statistical significance of the two effects is similar based on
the NLST data; even though the subgroup effect is larger in magnitude, it is eval-
uated in a smaller subpopulation, and these two aspects counterbalance each other
compared to the smaller ITT effect in the entire study population.
6 Discussion
In this paper, we proposed a simplified causal multi-state model to simulate screening
trials, and proposed a new measure (i.e. causal cause-specific hazard ratio) to quantify
the impact of early treatments compared to delayed treatments in the screening-
detectable subgroup. We note that the subgroup is specific to the screening regimen
and screening technology implemented in the trial that is used for the estimation,
as the effect is formulated in terms of a hypothetical intervention trial that shares
the same regimen and technology. We presented two alternative estimators for the
subgroup effect. In addition to comparing properties of estimators, the simulation
model may have use in planning new trials targeted for the subgroup effects.
While we contend that the cause-specific hazard ratio can serve as a useful sum-
mary measure of the magnitude of the effect, and simplifies accommodating competing
risks into the analysis, we do note that the use of marginal hazard ratios as a causal
parameters has been criticized by several authors (e.g. Aalen et al., 2015), who point
out even in randomized trials where the arms are initially balanced with respect to
observed or unobserved baseline characteristics, this balance is lost over the course of
the follow-up as more high risk individuals get removed from the risksets. However,
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Figure 3: Estimated effect of delayed versus early treatment on lung cancer mortal-
ity among the screening-detectable subgroup. The dashed lines are 95% bootstrap
confidence bands. Estimates are generated as a function of time, using the follow-up
data up to a given time point t. The estimates are noisy in the first year of follow-up
and are shown from the second year.
as outlined by Young et al. (2020), a causal cause-specific hazards can always be for-
mulated in terms of the underlying potential event time/event type outcomes in the
two arms of a trial. Because these quantities are defined conditional on the past, it
should be noted that the corresponding hazard ratio being one at a given time does
not necessarily imply the absence of a causal effect. If a strictly causal interpretation
is sought, one could use the subgroup mortality risk reduction as the measure instead.
With these reservations, we suggest interpreting the cause-specific hazard ratio as
a summary measure of the early treatment effect over time. However, we note that
the proportionality is more plausible for the subgroup early treatment effect since
this effect begins from the early diagnosis, compared to the use of cancer mortality
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rate ratio to compare the screening and control arms, which is dependent on the
screening regimen, among other things. In fact, we suggest that the present proposal
can resolve some of the controversies in characterizing screening effect through a
hazard/rate ratio, discussed for example by Liu et al. (2013, 2015); Hanley and Njor
(2018); Habbema (2018). Rather than the screening effect in the entire population,
what could be plausibly assumed proportional is the early treatment effect in the
subgroup. On the other hand, the usual residual type diagnostics for proportionality
violations are not applicable under the instrumental variable type estimation methods;
diagnosing violations of proportionality under the current framework is a topic for
further research. As one possible approach, the likelihood-based method would allow
testing the significance of interaction terms with time entered into the model. The
likelihood could also be used to assess on which time scale proportionality fits the
data better.
The estimation methods we outlined here could accommodate independent cen-
soring. They extend straightforwardly to the case where the censoring is conditional
on baseline covariates, for example, standardizing over the empirical covariate distri-
bution in the control arm of the trial, equation (5) can be expressed as
1
n
∑
{i:Zi=0}
E[N013(t) | xi]
=
1
n
∑
{i:Zi=0}
[∫ t
0
exp
{−(Λ112(u | xi) + Λ113(u | xi) + Λ114(u | xi))}λ112(u | xi)
×
∫ t
u
exp
{−(θΛ123(v | xi) + Λ124(v | xi))} θλ123(v | xi) dv du
+
∫ t
0
exp
{−(Λ112(u | xi) + Λ113(u | xi) + Λ114(u | xi))}λ113(u | xi) du
]
,
where the covariate conditional cause-specific hazards can be estimated using Cox
models, and the cumulative incidences on the left hand side either with Cox or Fine &
Gray models. In addition to allowing for covariate-dependent censoring, conditioning
on the covariates may be useful for relaxing the instrumental variable assumptions
outside of randomized trials, or improving the efficiency of the instrumental variable
type estimators (Burgess et al., 2017). We are currently pursuing these extensions.
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